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Bringing home baby
Sensitive, skilled fetal and infant care
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ERIC YOUNG

At home on the Plaza
This spring, a mallard family took up residence in the
Maya Lin-designed water feature on the Ellen S. Clark
Hope Plaza. The parents and ducklings proved a
popular attraction, often drawing crowds — many
taking photos with their cameras and phones —
that checked on the family’s progress and watched
the fledglings grow.

Outlook Autumn 2013
outlook.wustl.edu

Published by Washington University School of Medicine
Office of Medical Public Affairs, Campus Box 8508,
4444 Forest Park Ave., St. Louis, MO 63108 © 2013
PHONE (314 ) 286-0100 E-MAIL mpa@wustl.edu
EDITOR MARY ELLEN BENSON
ASSISTANT EDITOR, DESIGNER ERIC YOUNG
CONTRIBUTING EDITORS HOLLY EDMISTON, DEB PARKER
EXECUTIVE EDITOR DONNA HEROUX
PHOTOGRAPHER ROBERT BOSTON
CIRCULATION KATHI LAW

facebook.com/WUSTLmedicine.health
@WUSTLmedschool

ROBERT BOSTON

WEB PRODUCTION BRIAN MARSTON, AARON GRAHAM
AND THE MAGAZINE STAFF

Washington University School of Medicine
OUTLOOK.WUSTL.EDU

A U T U M N 2 0 13

5 Turtle holds

health clues

23 Tango therapy

Taking a Shine to Cells

XX Caption caption

10

Light can influence the behavior of
individual cells and cell networks, which
may one day benefit human health.

The Long Way Home

14

When expectant families learn their baby
has an abnormality, the Fetal Care Center
gives compassionate care and hope.

Choices for Lung Cancer Therapy

20

Patients with early-stage lung cancer receive
thoracic surgery or radiation therapy, but
sometimes the choice is not clear-cut.

Care to Tango?

23
COVER

Hayden Hoskins, born with
his abdominal organs outside his body, was
treated at the Fetal Care Center, where he
and his family received in-depth care. To
learn more about services for babies like
Hayden, please turn to page 14.
P H OTO BY R O B E RT B O S TO N

2
8
26

Surprisingly, dancing the tango seems to
improve the motor skills of people with
Parkinson’s disease.

Pulse
Viewpoint
Alumni & Development
26 Classnotes
28 Cancer and
Personalized Medicine

33 Genetic fingerprints of cancer

pulse

stovk

It’s a wrap!

A

mong the most common pediatric
injuries seen in emergency rooms
are fractures that occur when
children fall and try to catch themselves
with an outstretched hand.
For many, that tumble on the playground, around the bases or off a bunk bed
results in a buckle fracture, a forearm injury
traditionally treated with a cast.
But new research from the School of
Medicine shows that removable splints are
clearly preferred by patients and their parents, building on earlier findings that such
splints are just as effective as casts.
“Our goal is to manage these fractures
in a manner that allows healing while
maximizing comfort and convenience,
yet minimizing disruptions in children’s
active lifestyles,” says senior author Janet
D. Luhmann, MD, an associate professor of
pediatrics and physician in the emergency
department at St. Louis Children’s Hospital.
2 Washington University School of Medicine

Splints preferred over
casts for forearm
buckle fractures

“Traditionally, forearm buckle fractures
have been managed with casts, which can
be heavy, uncomfortable and, in the summer, hot and cumbersome. Without an
expensive liner, children can’t get them wet,
which results in significant inconvenience
regarding swimming and hygiene.”
The new findings, coupled with earlier
research into the effectiveness of splints
versus casts, have led to a change in the
standard treatment of these type of fractures at St. Louis Children’s. Now, prefabricated splints are the chosen treatment.

A significant percentage
of emergency department
visits involve children
seeking care for
orthopedic injuries.

Further, absent pain experienced by
patients, no longer is it recommended that
they follow up with orthopedic surgeons
and possibly undergo more X-rays. Rather,
explains Kristine G. Williams, MD, the study’s
lead author, children can be seen by their
pediatricians two or three weeks later.
The researchers’ findings are available
online in Pediatric Emergency Care.
Children’s bones, when compared with
the bones of adults, are less dense, more
porous and more likely to bend than break.
Buckle fractures are inherently stable and are
at low risk for displacement and complete
breakage, so they tend to heal well with
minimal intervention.
Study findings, authors say, show that
when treating uncomplicated buckle fractures near the wrist, splints are preferred by
patients and their parents — in addition to
being easier, less expensive and less timeconsuming than casts.
‘’Parents rated the splint higher in almost
all categories,” says Williams, an assistant
professor of pediatrics who treats patients at
St. Louis Children’s. “They tended to say they
would definitely choose the splint again over
a cast if they had a similar kind of injury.”
Autumn 2013

Bee venom kills HIV, leaves
normal cells unharmed

ELIZABETHE HOLLAND DURANDO

Nanoparticles carrying a toxin found in bee venom can
destroy human immunodeficiency virus (HIV) while leaving surrounding cells unharmed, researchers at the School
of Medicine have shown. The finding is an important step
toward developing a vaginal gel that may prevent the spread
of HIV, the virus that causes AIDS.
“Our hope is that in places where HIV is running rampant,
people could use this gel as a preventive measure to stop the
initial infection,” says Joshua L. Hood, MD, PhD, a research
instructor in medicine.
The study appears in the March issue of Antiviral Therapy.
Bee venom contains a toxin called melittin that can poke
holes in the protective envelope that surrounds HIV and
other viruses. Large amounts of free melittin can cause a lot
of damage. In addition to anti-viral therapy, the paper’s senior
author, Samuel A. Wickline, MD, the James R. Hornsby
Family Professor of Biomedical Sciences, has shown melittinloaded nanoparticles to be effective in killing tumor cells.
The new study shows that melittin loaded onto these
nanoparticles does not harm normal cells because Hood
added protective bumpers to the nanoparticle surface.
When the nanoparticles come into contact with normal
cells, which are much larger, the particles simply bounce off.
HIV, on the other hand, is even
smaller than the nanoparticle,
The findings from this
so HIV fits between the bumpers
study could apply to other
and makes contact with the surviruses as well, including
face of the nanoparticle, where
the bee toxin awaits.
hepatitis B and C, which
“Melittin on the nanoparticles
also rely on a protective
fuses with the viral envelope,”
envelope.
Hood says. “The melittin forms
little pore-like attack complexes
and ruptures the envelope, stripping it off the virus.”
Hood says an advantage of this is that the nanoparticle
attacks an essential part of the virus’ structure. In contrast,
most anti-HIV drugs inhibit the virus’ ability to replicate,
but this does nothing to stop initial infection.
“We are attacking an inherent physical property of HIV,”
Hood says. “Theoretically, there isn’t any way for the virus
to adapt to that. The virus has to have a protective coat, a
double-layered membrane that covers the virus.”
Beyond prevention in the form of a vaginal gel, Hood also
sees potential for using nanoparticles with melittin as therapy
for existing HIV infections, especially those that are drugresistant. The nanoparticles could be injected intravenously
and should be able to clear HIV from the bloodstream.
outlook.wustl.edu
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Findings may prevent spread of HIV

Newborn screening

On July 9 at St. Louis Children’s
Hospital, Missouri Governor Jay Nixon signed a bill integrating pulse
oximetry into routine newborn testing for critical congenital heart
disease. A pulse oximeter, a small cuff that fits around a baby’s hand
or foot, reads the level of oxygen in the blood, along with heart rate.
Sherrie M. Hauft, MD, Cynthia M. Ortinau, MD, and George F. Van Hare,
MD, from the Department of Pediatrics helped create the legislation.

Powderly named director of
Institute for Public Health
William G. Powderly, MD, the J. William Campbell
Professor of Medicine at the School of Medicine, has been
named director of the Institute for Public Health (IPH),
effective July 1, 2013. Powderly succeeds founding director
Edward F. Lawlor, PhD, dean of the Brown School and the
William E. Gordon Distinguished
Professor.
Graham A. Colditz, MD, DrPH,
the Niess-Gain Professor of Surgery,
continues to serve as deputy director.
“Washington University’s Institute
for Public Health has flourished
under the leadership of Eddie Lawlor,”
says Chancellor Mark S. Wrighton.
“Bill Powderly is the perfect person
to take the Institute to the next level,
and I’m grateful he has taken on this
leadership role.”
“I view my role as building on
William G. Powderly, MD
what Eddie Lawlor and Graham have
done,” Powderly says. He oversees all five centers and initiatives of IPH. “I look forward to working with Graham and
the other center directors.”
Powderly is co-director of the Division of Infectious
Diseases at the School of Medicine and director of the
Center for Global Health at IPH.
Outlook 3

Brain differences seen in
depressed preschoolers

Palmquist receives Dean’s Award

Kristin
E. Palmquist, right, nurse coordinator in the Washington University
Infectious Diseases Clinic, talks with co-workers Henry Westerfield
and Amber Gase, both medical assistants at the clinic. Palmquist
was awarded the Dean’s Distinguished Service Award, the School of
Medicine’s highest honor for staff. “She goes above and beyond the
call of duty on a daily basis to help provide world-class care,” wrote
Lori Watkins, the division’s nurse manager.

Grant benefits young scientists
Thanks to a grant from the St. Louis-based Edward
Mallinckrodt Jr. Foundation, 21 physician scientist trainees
in two clinical departments — Medicine and Pediatrics —
at the School of Medicine will receive research support.
Physician scientist trainees graduate with combined
medical and doctoral degrees and usually pursue faculty
positions that allow them to treat patients and conduct
laboratory research.
Victoria J. Fraser, MD, the Adolphus Busch Professor and
head of the Department of Medicine, says the Mallinckrodt
Foundation gift comes at a crucial
time, given the current cuts to
The grant expands the
National Institutes of Health (NIH)
support of physician
funding.
scientist trainees from
The grant, says Stuart A. Kornfeld,
MD,
co-director of the physician scithree to 21 each year.
entist training program, “will allow a
major expansion of these programs.”
The gift is being given in honor of the late Oliver M.
Langenberg, who led the Mallinckrodt Foundation for more
than 50 years. The physician scientist training programs
in medicine and pediatrics will be renamed the Oliver
Langenberg Physician Scientist Training Program.
Alan L. Schwartz, MD, PhD, the Harriet B. Spoehrer
Professor and head of the Department of Pediatrics, says that
the gift is a perfect way to honor Langenberg, who placed
great value on developing future leaders. The Mallinckrodt
Enjoy interactive elements and added content
Foundation’s grants to the School of Medicine have totaled
$14.6 million.
4 Washington University School of Medicine

The first study of children so young
A key brain structure that regulates emotions works differently in preschoolers with depression compared with their
healthy peers, new research at the School of Medicine shows.
The differences, measured using functional magnetic
resonance imaging (fMRI), provide the earliest evidence yet
of changes in brain function in young children with depression. The researchers say the findings could lead to ways to
identify and treat depressed children earlier in the course
of the illness, potentially preventing future problems.
“The findings really hammer home that these kids are
suffering from a very real disorder that requires treatment,”
said lead author Michael S. Gaffrey, PhD, assistant professor
of psychiatry. “We believe this study demonstrates that there
are differences in the brains of these very young children and
that they may mark the beginnings of a lifelong problem.”
The study is published in the July issue of the Journal of
the American Academy of Child & Adolescent Psychiatry.
Depressed preschoolers had elevated activity in the brain’s
amygdala, an almond-shaped set of neurons important in
processing emotions. Earlier imaging studies identified similar changes in the amygdala region in adults, adolescents
and older children with depression, but none had looked
at preschoolers.
For the new study, scientists from Washington
University’s Early Emotional
Development Program studied 54 children ages 4 to 6.
Before the study began, 23
of them had been diagnosed
with depression. The other
31 had not. None had taken
antidepressant medication.
While in the fMRI, the
children looked at pictures
of people whose facial
expressions conveyed parBrain scans of preschoolers with depression
ticular emotions — happy,
revealed elevated activity in the amygdala.
sad, fearful and neutral.
“The amygdala region
showed elevated activity when
the depressed children viewed pictures of people’s faces,”
says Gaffrey. “We saw the same elevated activity, regardless
of the type of faces the children were shown.”
The depressed preschoolers’ responses were somewhat
different from those previously seen in adults, where the
amygdala responds more to negative expressions of emotion.
Autumn 2013
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GOODY CLANCY + CHRISTNER

In the works

The School of Medicine is
constructing an energy-efficient, multistory building
dedicated to interdisciplinary research on some of the
most complex problems in human biology. Positioned
along McKinley Avenue just west of Taylor Avenue,

the facility eventually will house 138,000 square feet
of highly flexible, open laboratories — spaces that
can evolve to meet future trends and changing needs.
Planners broke ground on the $75 million facility this
summer with a June 2015 target date for completion.

GENETICS

outlook.wustl.edu

body design that has changed little over
the past 210 million years, the authors note.
Unlike other reptiles, turtles sport a sharp
beak instead of teeth and live encased in a
hard shell, a convenient home in which to
hide when danger lurks.
“Turtles are nothing short of an enigma,”
says senior author Richard K. Wilson, PhD,
director of Washington University’s Genome
Institute. “They may be slowly evolving, but
turtles have developed an array of enviable
features. They resist growing old, can reproduce even at advanced ages, and their bodies
can freeze solid, thaw and survive without
damaging delicate organs and tissues. We
could learn a lot from them.”
A close look at the turtle genome reveals
that these creatures do not rely on novel
genes for their unique physiological adaptations, such as the ability to withstand oxygen
deprivation. Rather, they activate gene networks common to most vertebrates, including
humans, but use those genes in different
ways. “This is a back door route for turtles to
evolve,” says co-author Patrick Minx of The

The evolution of turtles — like their gait — is slow.
Genome Institute. “Rather than evolve new
genes, they adapted existing genes.”
The scientists identified 19 genes in the
brain and 23 in the heart that are activated
in low-oxygen conditions. These genes also
are present in humans and may be important candidates to explore for treatments to
reduce tissue damage due to oxygen deprivation. They also identified common patterns
of gene loss in the turtle associated with longevity, sex determination and a lack of teeth,
findings that warrant further investigation.
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cientists have decoded the genome
of the western painted turtle, one of
the most abundant turtles on Earth,
finding clues to its longevity and ability to
survive without oxygen during winters spent
hibernating in ice-covered ponds.
Understanding the mechanisms turtles
use to protect the heart and brain from
oxygen deprivation may one day improve
treatments for heart attacks or strokes, the
researchers say. Both can lead to severe disability or death within minutes in patients
deprived of oxygen.
The research team includes scientists at
Washington University School of Medicine,
the University of California at Los Angeles,
Saint Louis University and other institutions.
Their analysis is now available online in
Genome Biology.
New data confirm that the turtles’ pace of
evolution parallels their speed on the ground.
It’s exceedingly slow, about one-third of the
rate of human evolution and one-fifth the
rate of the fastest evolving python.
In fact, turtles have evolved a distinctive

TRACEY HAYNES

Painted turtle DNA holds health clues

pulse

St. Louis
Cardinals left fielder Matt Holliday and his mom, Kathy, are joining
forces to spread the word about the importance of colon cancer
screening. Kathy, who battled the disease last year, says screening
saves lives. The two are teaming up with the Alvin J. Siteman Cancer
Center at Barnes-Jewish Hospital and Washington University School of
Medicine to encourage colon screenings for anyone age 50 and older.

Elson recognized for research efforts
Elliot L. Elson, PhD, has been elected a fellow of the American
Academy of Arts and Sciences.
Elson, the Alumni Endowed Professor of Biochemistry
and Molecular Biophysics, is one of 186 Americans elected
as fellows this year by the academy, an organization formed
in 1780 to cultivate the arts and sciences and to recognize
leadership in scholarship, business,
the arts and public affairs.
“I am delighted that a member
of our outstanding faculty has
received this tremendous honor,”
says Chancellor Mark S. Wrighton.
“Dr. Elson is a dedicated scientist,
and this recognition is well-deserved.
This achievement demonstrates
the good fortune we have had at
Washington University in attracting
premier faculty.”
Elson also is a professor of
Elliot L. Elson, PhD
biomedical engineering in the
School of Engineering & Applied Science and an adjunct
professor of physics in Arts & Sciences. His research focuses
on cellular motion, the movement and distribution of cell
surface proteins and the forces that determine the shapes
of cells. He and members of his lab also have studied artificial cardiovascular tissues, including their mechanical and
electrical properties.
Elson and his lab members are well-known for designing
and building unique scientific instruments for highly specialized inquiries. One such instrument evolved from a novel
technique to measure molecular motion.
6 Washington University School of Medicine

Jess and Alice Yawitz, whose relationship with Washington
University goes back more than 40 years, have established the
Dr. Phillip and Arleen Korenblat Professorship in the School
of Medicine. Jess Yawitz, AB ’68, MA ’69, PhD ’72, majored
in economics and served on the faculty of the Olin Business
School, where Alice Yawitz earned her MBA degree in 1975.
Supporters of several university schools and programs, the
Yawitzes’ long association with St. Louis physician Korenblat,
MD, spurred their decision to endow the professorship.
“I would come home from my physical with Phil, and say,
‘Phil is so good,’” says Jess Yawitz. “And my wife would say,
‘He’s the best.’ After a while, it was obvious we needed to do
something to honor him and Arleen.”
An internist in private practice who specializes in allergies
and asthma, Korenblat has cared for many members of the
Yawitz family. His own Washington University connection is
strong: He completed an internal medicine residency in 1965
and serves as a clinical professor at the School of Medicine.
He has received many honors, including a Distinguished
Service Award from the Washington University Medical
Center Alumni Association. Arleen Korenblat has been
a benefactor and
volunteer for many
organizations.
While the Yawitzes
knew Korenblat primarily as a physician,
Jess Yawitz also knew
his reputation as an
outstanding educator.
“When I would visit
him, he frequently
had Washington
University residents
trailing him. He
seemed keen on pass- Arleen and Phillip Korenblat, MD
ing wisdom down to the next generation,” Yawitz says.
As did Yawitz himself. He joined the Olin School faculty in
1971 and became the John E. Simon Professor of Finance in
1981. In 1985 he joined Goldman Sachs in New York, returning to St. Louis in 1988. He currently serves as the chairman
and chief executive officer of NISA Investment Advisors.
H. James Wedner, MD, was installed as the Dr. Phillip
and Arleen Korenblat Professor of Allergy and Immunology
in Medicine on June 6, 2013. He is chief of the Division of
Allergy and Immunology in the Department of Medicine,
and his specialty areas include sinus disease and asthma.
Autumn 2013
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‘Cancer doesn’t take a Holliday’

Clinician and educator is “the best”

MARK BEAVEN

COURTESY OF SITEMAN CANCER CENTER

Couple honors their physician
and friend with professorship

Lines in the circos plot
connect major genes
involved in acute myeloid
leukemia with patients
whose leukemia cells have
mutations in those genes.

The trailblazers

In the footsteps of Lewis and Clark — science team
forges new exploration in gene mapping

A

team of researchers led by
Washington University School
of Medicine has identified
virtually all of the major mutations that
drive acute myeloid leukemia (AML), a
fast-growing blood cancer in adults that
often is difficult to treat.
The findings, published online in The
New England Journal of Medicine, pave
the way for developing better treatments
for AML based on the genetic profile of a
patient’s cancer. They also could lead to
ways to more accurately predict the severity
of disease in individual patients.
“We now have a genetic playbook for
this type of leukemia,” says study co-leader
Timothy Ley, MD, the Lewis T. and Rosalind
B. Apple Professor of Oncology in the
Department of Medicine. “We don’t know
all the rules yet, but we know all the major
players. This information can help us begin
to understand which patients need more
aggressive treatment right up front and
which can be treated effectively with standard chemotherapy.”
Some 200 patients newly diagnosed
with AML were involved in the study,
funded by the National Institutes of Health
(NIH) as part of The Cancer Genome Atlas
outlook.wustl.edu

project. Nearly 150 researchers were
involved in the effort.
A second Cancer Genome Atlas paper
was published in May in Nature. That
research, also led by the School of Medicine
and focusing on endometrial cancer, shows
that adding genomics-based testing to the
standard diagnostic workup could change
the recommended course of treatment for
some women.
For the leukemia study, the scientists
sequenced the DNA of each patient’s
leukemia cells and compared the data to
DNA from each patient’s healthy cells. They
found the mutations that only occurred
in the cancer cells and contributed to the
development and progression of AML in

Like Lewis and Clark’s
famous expedition of the
American frontier, the
new survey of leukemia
genomes began in St. Louis
and is an exploration with
long-lasting influences.

each patient. They also looked for defects
in RNA (a close chemical cousin of DNA) and
other changes that alter the expression of
genes without actually changing the DNA.
“These results provide important new
insights into the genomics of a deadly and
difficult-to-treat cancer, and underscore the
power and scope of The Cancer Genome
Atlas project,” says NIH Director Francis S.
Collins, MD, PhD.
Compared to other adult cancers, AML
is caused by relatively few mutations.
Cancer cells in the AML patients had an
average of 13 mutated genes, far fewer
than the several hundred typically found
in breast, lung and other solid tumors.
By studying a large number of AML
cases, the scientists predict they have found
nearly all of the major mutations that occur
in patients with the disease.
“If only 5 percent of AML cases have a
particular gene that is mutated, there is a
greater than 99 percent chance that we
encountered that mutation at least once in
this study,” says co-leader Richard K. Wilson,
PhD, director of Washington University’s
Genome Institute and research member
of the Siteman Cancer Center. “There are
still rare mutations that remain to be
discovered, but we expect they will fall
into the same genetic pathways or gene
sets that we identified as being very
strongly associated with AML.”
An estimated 14,600 Americans will
be diagnosed with AML this year and some
10,400 will die. Unfortunately, few good
markers exist to help guide treatment
decisions for many patients.
Outlook 7
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In his role as associate dean for admissions, W. Edwin Dodson, MD, center, has nourished relationships with medical school applicants, students and colleagues.

Bringing
out the

BEST
(and the brightest)

O

utstanding colleague, student mentor,
superb physician and educator — these
are just some of the ways that colleagues

describe W. Edwin Dodson, MD, professor of pediatrics and neurology, associate vice chancellor and
associate dean for admissions and financial aid.
As Ed Dodson retires at the end of 2013, he
will leave behind a legacy of passion, commitment
and ethic of duty. Indeed, it’s hard to separate his
many accomplishments in admissions from his
remarkable career in pediatric neurology and his
tireless devotion to community service.
For four decades Dodson has nurtured caring,

Ed Dodson, MD, begins his
next chapter having started
thousands of students in the
practice of medicine.
BY HOLLY EDMISTON
8 Washington University School of Medicine

compassionate relationships with his patients and
their families. For the last 23 years, he also has
worked passionately to bring the very best students
to Washington University School of Medicine.
And which aspect of his career will he miss
most? Dodson replies: “I’ll miss it all.”
Autumn 2013

Ed Dodson on . . .
the practice of pediatric neurology
“For me, it’s always been about minimizing the impact
of the person’s illness or problems so they can pursue
their dreams. It’s hard to describe how attached
one becomes to patients and their families. I’ve had
remarkable continuity with my patients because they
tend to have neurological disorders that don’t go away;
I see families that I’ve followed for more than 30 years.
I feel doubly blessed to be a physician and have such
rich relationships.”

ROBERT BOSTON

being dean of admissions
“It’s easy to understand why people dwell so long in
this position — you interact with spectacular colleagues
from around the medical school and with students
throughout their four years or more. And then you
have the opportunity to get to know some of the
brightest and best young people in America who are
applying to medical school. It’s absolutely a gift, and
just a lot of fun.”

some of the hurdles overcome in admissions
“I do think that the medical school and the medical
community have addressed the issue of gender imbalance;
it’s pretty much become a gender-neutral process.
“The issue of maintaining diversity in the class is an
ongoing challenge. There’s a short supply of historically
underrepresented minorities in the applicant pool:
Mexican-Americans, Puerto Ricans, Native Americans
and African Americans. Medicine has not been as
attractive to them as it should be, so the competition for
underrepresented minority students is very intense.
“There’s a lot of work taking place on bringing young
people at the grade school, middle school and high
school level into the medical community, but they need
academic enrichment to be prepared for the competitive
rigors of medical school. So it’s really a pipeline issue,
an issue of making certain that the people you bring
into this environment have the skills to succeed.”

current and future challenges in admissions
“Medical school admissions is biased toward people
from affluent families. These people have the financial
resources and come from families who value education.
They go to the most selective elementary, middle and
high schools and then on to the most selective colleges,
so they come out with a substantial advantage. One of
the ongoing challenges in medical school admissions is
to try to get a class that’s also socioeconomically diverse,
people who have life experiences that broaden the
outlook.wustl.edu

experience of the entire class. Medical students spend
more time with their classmates than they do with any
other group of people. They really have a lot of impact
on each other, and they often see the world through
each other’s eyes. A diverse class enriches the experience
for the students and the faculty.”

why WUSM remains No. 1 in student selectivity
“I think this is a spectacular place. I think incoming
students come and talk to our current students and
understand that our students are nurtured, supported
and encouraged; they recognize that this is a place
that tries to bring out the best in everybody in our
community. Students come here and expect that because
we have such high academic credentials that they’re
going to see a bunch of competitive, gnarly people, and
in fact, just the opposite’s true. They come here and
see people who are supportive and are helping each
other. They come to an environment where everybody
succeeds; no one has to fail.”

his legacy and retirement
“I hope that I’ve communicated to students that it’s
OK to do your best, and it’s OK to do something big.
The practice of medicine is a privilege and it’s a lot of
fun. The hope is that people who come to medicine
will be excited by it every day, so they get up and feel
happy about the activities that lie ahead. When the
opportunities come along to do something big, I hope
our students won’t shy away from them.
“I plan to dismiss my patients but look forward to
continuing to interact with residents and their patients.
I love fly-fishing, and I want to spend time with my
great wife, and with friends and my 11 grandchildren
in beautiful places.”

We’re number

Seriously, folks!
Clown arts enhance
the healing arts.

Since 1990, W. Edwin Dodson, MD, serving as
associate dean for admissions and financial aid,
has led the School of Medicine in recruiting
remarkable students from all walks of life.

No. 1 in student selectivity

according to U.S. News & World Report

Highest academic credentials

of any class of medical students in the nation

30%

50%

5%

15%

increase in the number of female students
improvement in minority representation
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Taking a
shine to

CEL

Lighting the way to understanding the workings of cells,
network activities and possible future therapies B Y J I M D R Y D E N
Light already has a major role in medicine —
specific wavelengths of light are used in various treatments
and research efforts — but that role may be growing.
X-rays, which are invisible to the eye, can make the stuff
inside us visible. Ultraviolet light can treat skin diseases
such as psoriasis. And bright light boxes help stabilize
the moods of patients with seasonal affective disorder.
Beyond these applications, investigators at the School
of Medicine’s Department of Anesthesiology are using
genetic engineering to influence how cells respond to light.
One team is investigating proteins in the eye called
opsins, which allow photoreceptor cells to convert light into
vision and enable us to see, to activate other types of cells.
This allows the scientists to use light to control cell behavior.
Other investigators are working with optogenetics —
using light to influence specific neurons in animals in order
to map brain circuits and understand complex behaviors
related to sleep, depression, anxiety and pain.
Potentially their findings could allow the development
of precisely targeted light-based therapies.

10 Washington University School of Medicine

Ajith Karunarathne, PhD,
activates opsin-expressing cells
with a selected wavelength of
light in an imaging laboratory.
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Opsins can do more than “see” in the way we typically

think of seeing. In fact, they can activate cells to respond
to their environments.
N. Gautam, PhD, professor of anesthesiology and genetics,
and postdoctoral research associate Ajith Karunarathne, PhD,
are exploring how light can cause opsins to behave in cells.
When they inserted opsin proteins, which are G proteincoupled receptors (GPCRs), into cells, they found that by
shining light on the cells, they could activate specific areas.
This bit of genetic engineering permits opsins to activate
other types of cells.
“Some of these opsins have properties that we thought
might allow us to localize the signaling activity in a cell to a
particular location in the cell,” says Gautam. “So we began
experimenting, and we found that we could, in fact, localize
the signaling to one side of the cell or another. A great deal
of cell behavior results from signaling where the cell will
sense something on its right, for example, and then move
toward that substance, or move away from it.”
An immune cell, for instance, that receives a signal and
senses a bacterial infection or inflammation, will travel in
the direction of the bacteria or the inflammatory molecules.
When Gautam and Karunarathne inserted opsins into
immune cells, the cells moved towards a light beam.
“We can use light as a kind of ‘on-off’ switch to control
cell behavior,” says Gautam. “Much of the way cells behave is

due to their ability to sense signals in the environment.
In our experiments, the cells sense the presence of light.”
In neurons, they have used light to coax the cells into
growing new branches called neurites. They are planning
similar things in heart cells and in pancreatic cells.
The goal with the heart cells would be to use light to
slow down, or speed up, the rate at which the cells pulse.
In pancreatic cells, they want to use light to get the cells
to secrete insulin.
“We believe that with these techniques, it’s likely that
any process that can be controlled by signaling from GPCRs
can also be controlled by light,” Gautam says.
Although Gautam believes that inserting opsins into cells
has immense therapeutic potential, he says it will be a while
before the strategy is ready for clinical use. For one thing,
it will require gene therapy in order to introduce the lightsensitive proteins into specific cell populations. For another,
it will require a way to introduce light into cells deep inside
the body, perhaps using micro-light emitting devices (LEDs).
While his laboratory is working on ideas to take this
strategy from the culture dish into whole animals, they
also are creating a library of several different opsin proteins
capable of controlling cell behavior.
“As we move forward, one of our goals is to continue
testing multiple opsins from different organisms to learn
which ones work best,” he says.

Y

ou can see this page because your eyes
have opsins — light-sensitive receptors in
cell membranes — responding to varying
light. Those subtle, natural responses suggest
a daring idea: What if other body cells were
modified to respond to light? Immune cells could
speed toward a lighted wound; light pulses could
regulate a heartbeat. This experimental concept
is more useful than a simple on/off toggle;
think of it more like a dimmer switch that can
control the intensity of the response. Exploring
various creatures’ opsins — from pufferfish to
mosquitoes — will provide additional insights.
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With light-sensitive opsins added to its
membrane, this immune cell responds
to the light and moves toward it as
researchers move the pinpoint laser.
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Moving single cells

Activating cells in a network
Light can influence neurons in animals that have been

genetically engineered so that specific neurons will be activated and respond to light. Michael R. Bruchas, PhD, assistant professor of anesthesiology, and Robert W. Gereau IV,
PhD, professor of anesthesiology and of neurobiology, are
part of a group of scientists working in optogenetics.
Through their work with collaborator John A. Rogers,
PhD, and engineers at the University of Illinois, they
received a $3.9 million Transformative Research Project
award supported by the National Institutes of Health (NIH).
The researchers developed microscale, light-emitting
devices (LEDs) — the first use of these devices in optogenetics — that allow them to map the properties of neural circuits involved in injury, pain, anxiety and other problems.
Bruchas was able to implant the devices in mice, prodding
their neurons to release dopamine, a chemical associated
with pleasure. Because the LEDs are wireless and tiny, they
don’t interfere with normal behaviors. The mice move freely
about their cages and can explore a maze or run on a wheel.
Bruchas and the investigators taught the mice to poke
their noses through a specific hole in a maze. Each time, the
system wirelessly activated the micro-LEDs, which emitted
light, causing neurons to release dopamine.
“The micro-LEDs activated networks’ cells that are influenced by the things humans also find rewarding, like sex
or chocolate,” says Bruchas. “When the cells were activated

to release dopamine, the mice quickly learned to poke their
noses through the hole even though they didn’t receive food
as a reward.”
He says the devices should allow scientists to identify
and map brain circuits involved in many complex behaviors.
“Understanding which populations of neurons are involved
in these complex behaviors may allow us to target specific
brain cells that malfunction in depression, pain, addiction
and other disorders,” Bruchas says.
In Gereau’s laboratory, the devices are implanted near
peripheral nerves to interrupt or redirect pain signals.
“Rather than identifying specific stimuli, we just want to
turn off the cells causing pain,” says Gereau, who is director
of the Washington University Pain Center.
But before those devices will relieve pain or stress,
patients will need gene therapy that makes certain cells
respond to light signals.
Gereau believes a common-sense strategy for doing so
lies in a viral attack on the peripheral nervous system.
“If we can find a way to use a harmless version of the
herpes simplex virus to deliver light-sensitive proteins to
peripheral nerve cells, we believe we may be able to control
the activity and signaling of those cells,” says Gereau.
Bruchas, Gereau and colleagues hope that someday their
work with micro-LEDs may illuminate ways of controlling
behavioral disorders and pain in humans.

D

epression, pain, stress, addiction —
which cells play a part? Micro-scale
lights (smaller than the eye of a needle)
can help illuminate these vexing questions.
For example, in the mammalian brain at right,
only genetically modified, light-sensitive neurons
are activated, resulting in modified behaviors.
There may be a way — perhaps via a harmless
virus — to deliver light-sensitive proteins to
human nerve cells. These bright ideas could
someday alleviate pain, modify mental disorders
and otherwise improve the human condition.
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hen ultrasound screenings in pregnancy
indicate that babies’ tiny systems may be
developing irregularly, or family medical
histories suggest anomalies may occur, doctors from
around the region refer mothers to the Fetal Care Center
(FCC). With their hopes badly shaken for an uneventful
pregnancy and a healthy baby, families arrive at the center
longing for answers, for interventions from medical science,
for hope. And they find these things, in their many forms,
as they are guided through a compassionate sequence of
physical and emotional care.
FCC medical co-director and neonatologist Barbara
B. Warner, MD, MSCE, specialized in newborn medicine
because she was drawn to working with ill and premature
newborns and their families. “Helping and supporting
is a great privilege,” says Warner, professor of pediatrics
in the Department of Pediatrics, whose neonatal group
is ranked among the top three in the United States,
according to U.S. News & World Report.
Adds medical co-director and medical geneticist
Lisa M. Bernhard, MD, “With our comprehensive, in-depth
care, we give babies their very best possible chance. We
do all we can to make these terribly stressful months in
families’ lives as easy and as seamless as possible.”
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One to grow on: Dillon, who
was treated for congenital
pulmonary airway malformation, with his mom, Carol
Waeckerle, and Fetal Care
Center co-directors Barbara
B. Warner, MD, MSCE, left,
and Lisa M. Bernhard, MD.
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Delivering exceptional care
when expectant families
face the unexpected
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Although every major medical center has some type of

coordinated fetal care, center founder and director George
A. Macones, MD, MSCE, explains the goal of the Fetal Care
Center, which is a joint effort of Washington University
School of Medicine, Barnes-Jewish Hospital and St. Louis
Children’s Hospital.
“We are fully focused on our patients — mother and baby
— and the family. We bring very upset parents into the Fetal
Care Center, which is part of a complex quaternary medical
center made up of world-class physicians and hospitals, but
we make sure they get lots of information and know we’re
taking complete care of them through this difficult time,”
says Macones, the Mitchell and Elaine Yanow Professor, head
of the Department of Obstetrics and Gynecology, and that
department’s director of maternal–fetal medicine and ultrasound. “That special care isn’t just during the initial evaluation: It extends through pregnancy, delivery and afterward.”
Macones is internationally known as a clinician and perinatal
clinical researcher.
Overseeing all the personal attention patients receive is
a nurse coordinator at the FCC or, if a cardiac problem is
involved, from the Fetal Heart Center, part of the St. Louis
Children’s and Washington University Heart Center. Nurse
coordinators like Christine Hoover, BSN, RN, are a resource
and partner throughout the journey to delivery. “We’re with
families from the time they arrive until we walk them to
their car,” she says. Nurse coordinators accompany mothers
to all tests, meetings and consultations, “making sure everyone is on the same page and answering families’ questions.
“We also tour the facilities to help parents feel comfortable,” Hoover continues. “If we see it’s too much, we stop.”
Recently a mother told Hoover, “Yes, I really want to see the
NICU.” But when they entered the hushed, darkened room,
where sick infants slept next to sophisticated instrumentation and some parents sat crying, she burst into tears.
“We postponed the rest,” Hoover says. “We always act
on the patient’s wishes, including rescheduling appointments
and obtaining temporary physician privileges at BarnesJewish if a patient wants her own obstetrician to deliver her
baby. As many as 12 extended family members have attended
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Caroline K. Lee, MD,
consults with
mother Misty
Nutter and baby
Austin Rakers.

COURTESY OF ST. LOUIS CHILDREN’S HOSPITAL
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Personal touch: Nurse coordinator Christine Hoover, left, walks mom Theresa
Clark through her scheduled visits in the Center for Advanced Medicine.

consultations! We do everything we possibly can to make
things better.”
Diagnosing a fetal anomaly that confirms or modifies a
referring physician’s finding — or discovering that the fetus
is normal — is the work of the ultrasound and genetics side
of maternal–fetal medicine. “When we find an abnormality,
we look very carefully for other problems, because very often
when one exists, other conditions are present that may not
have been identified,” says Bernhard, assistant professor of
obstetrics in the Department of Obstetrics and Gynecology’s
Division of Maternal–Fetal Medicine (MFM). “Then we
discuss what, with patient consent, should be done — such
as amniocentesis or a fetal MRI — to try to discover why a
particular birth defect has occurred.” Following the comprehensive assessment, “We go in right away to talk with the
parents, and then we contact the referring physician.”
Jacqueline Turner, MD, of West End Ob/Gyn, in St. Louis,
sends all her pregnant patients to the ultrasound and genetics
group for their early, routine ultrasound. “We prefer that
those physicians do the screening,” she says, “because if
there’s an issue, we know they’ll find it. If something major
is wrong, they actually call me at the time they’re doing the
ultrasound.” For families and referring doctors alike, she
adds, the FCC is a “great service.”
Leading the ultrasound and genetics team is maternal–
fetal medicine specialist Anthony A. Odibo, MD, MSCE,
whose ultrasound and fetal-abnormality research is known
worldwide. Odibo is also skilled in treating Twin-Twin
Transfusion Syndrome (TTTS), which can affect identical
twins who share a single placenta. In this condition, one twin
transfuses blood to the other, producing anemia and drastically slowed growth in the donor and excessive growth and
blood volume in the recipient.
He and his colleagues also use endoscopic surgery to place
shunts in tiny obstructed bladders, and they correct amniotic
band syndrome, wherein a strand of the amniotic sac membrane has wrapped itself so tightly around the baby that loss
of digits or blocked placental blood delivery can occur.
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Ultrasound diagnostics
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Anthony A. Odibo, MD, MSCE, professor of
obstetrics and gynecology and an international leader in ultrasound and fetal
abnormality research, leads the Fetal Care
Center’s ultrasound and genetics group.
Ultrasound is one of a range of diagnostic
tools used to screen pregnant patients like
Graziele Pacheco.

“We provide evidence-based, safe care,” says Odibo, professor of obstetrics and gynecology and vice chair for women
and fetal imaging. “Before we use new procedures in which
some risk may be involved, the situation must be one in
which we know definite evidence exists that prenatal surgery
or intervention is better than doing nothing. That’s where we
differ from some of our competitors.”
Fetal cardiac problems account for about 50 percent of

anomalies seen at the Fetal Care Center. In all cases, once
the MFM specialists have examined the heart and the whole
baby, fetal cardiac nurse coordinator Kym Galbraith, BSN,
RN, accompanies mother and family to the adjacent Fetal
Heart Center. There, pediatric cardiologists use echocardiography in a 30- to 60-minute noninvasive test to check cardiac
function and structure.
“Our heart center is completely full-service,” says
Caroline K. Lee, MD, assistant professor of pediatrics,
associate director of the Pediatric Cardiology Fellowship
Program and director of fetal cardiology. “Every heart
specialty is represented.”
The professional roster at Children’s, a leading transplant
center, includes three electrophysiologists, not found at many
centers, three cardiac catheterization physicians and 50 specialists who can administer extracorporeal membrane oxygenation (ECMO), an advanced treatment that does the work
of heart and lungs. The hospital’s pediatric subspecialists
represent every existing category, ready to step in as needed
before and after delivery, and newborn neurology provides
neurological imaging, monitoring and consultation.

When a sick infant is born at Barnes-Jewish Hospital, with
every necessary expert in attendance, the child is stabilized
and placed in a life-supporting isolette. A specialist takes the
outlook.wustl.edu

newborn and father to the Newborn Intensive Care Unit
(NICU), where a neonatology nurse coordinator waits.
The mother and an attendant visit shortly afterward. Seeing
their infant for the first time marks the start of a second,
hopeful journey for many parents, who have already learned
about planned treatments or surgeries.
But about 20 percent of FCC families, says Warner,
“have infants with lethal disorders. And while we may not
be able to reverse that process, we provide the baby with
warmth, pain medication — whatever he or she needs to
be comfortable. And if a baby will die, we can still provide
the family with a meaningful experience with their child
that they’ll always cherish.”
Regardless of the prognosis, Joan L. Rosenbaum, MD,
director of palliative care and professor of pediatrics, is
central to providing comfort and support. Rosenbaum
gets to know the families personally in the months
before birth and helps them identify their wishes. Among
these may be spiritual requests, such as wanting their
infant baptized.
“Joanie writes a beautiful letter detailing the parents’
wishes, so that they are communicated to everyone involved
in their infant’s care,” says Hoover, the nurse coordinator.
“Just last week, a family from southern Missouri met with
her. The first hospital they visited wouldn’t allow them to
have a photographer and other simple things that would
mean everything to them. They decided to come here for
care because they felt, in the mom’s words, that we honored
her and her baby and valued them both.”
As the FCC looks to the future, one goal is overarching.
And that, as Lisa Bernhard puts it, is further refining and
focusing on the patient experience.
“Our physicians and staff care so much more than our
patient families even realize,” says Christine Hoover.
Outlook 17
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The promise of a healthy pregnancy
sometimes changes in a heartbeat.
The Fetal Care Center (FCC) helps
these mothers and families walk
their more challenging paths, offering
world-class medicine in a sensitive,
caring environment.
Visit FetalCare.org
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Cause for concern

A routine checkup near the end of the first trimester
indicates a possible anomaly in the pregnancy.
The woman’s physician refers her to the FCC for
further evaluation.

All things considered

A nurse coordinator welcomes the family and
escorts them through the diagnostic sessions.
Single problems can signal multiple issues;
tests range from imaging to genetics and more.

Family matters

The FCC responds with sensitivity and respect to
families’ needs during these difficult, stressful days.
The prognosis is carefully considered and support
provided for making choices and moving forward.
Autumn 2013
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Go, Team
Hayden!
The journey continues

In utero interventions may be essential for further
diagnoses or to stabilize the pregnancy. The care
team coordinates an evidence-based medical plan
that maximizes health benefits and minimizes risks.

The big day arrives

A team of specialists stands ready to deliver skilled
care before, during and after delivery. Every baby
has a spectrum of special needs; the team works to
meet those needs and honor the family’s wishes.

Newborn and beyond

Very sick infants receive optimal care during their
too-short lives. Many more babies will benefit from
specialty procedures during the months ahead,
helping ensure lifetimes of happy birthdays.

outlook.wustl.edu

Hayden Hoskins is just one
of the many infants cared
for at the Fetal Care Center.
Ultrasound revealed Hayden’s
omphalocele; his organs were growing
outside his belly. Parents Andy and
Kelsea were referred to the FCC. After Hayden was
delivered at Barnes-Jewish Hospital, he was rushed
to the NICU at St. Louis Children’s Hospital. Five
months later, a surgical team placed his organs
internally. Today, Hayden has a lot to smile about.
HAYDEN’S TEAM: Christine Hoover, BSN, RN, nurse coordinator;
Brittany Knipstein, MD, fellow, neonatology; Brad W. Warner, MD,
the Jessie L. Ternberg, MD, PhD, Distinguished Professor of
Pediatric Surgery and surgeon-in-chief, St. Louis Children’s Hospital;
baby Hayden Hoskins; parents Andy and Kelsea Hoskins;
Alison G. Cahill, MD, MSCI, assistant professor of obstetrics and
gynecology; Shannon Waller-Reed, BSN, RN, nurse coordinator
Outlook 19

Minimally
invasive
surgery

C HOIC
Stereotactic
body radiation
therapy
20 Washington University School of Medicine
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Jeffrey D. Bradley, MD, right,
confers with dosimetrist Michael B.
Watts regarding a patient’s
SBRT treatments.

Deciding between two cancer therapies
B Y C A N DAC E O ’CO N N O R

LEFT TO RIGHT: ERIC YOUNG, ROBERT BOSTON, RUDI J. BERTRAND

Traves D. Crabtree, MD,
right, and Varun Puri, MD,
center, work with a surgical
team to remove a tumor.
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eek after week, newly diagnosed patients with earlystage lung cancer — mostly men in their mid-60s
who are longtime smokers — come to Washington
University physicians, seeking a successful form of treatment. If
they are otherwise healthy, thoracic surgeons Traves D. Crabtree,
MD, and Varun Puri, MD, perform minimally invasive surgery
to remove the lesion; if they have complicating conditions that
preclude surgery, radiation oncologist Jeffrey D. Bradley, MD, relies
on stereotactic body radiation therapy (SBRT). But for patients in
the gray area between the two extremes, which treatment is best?
For several years, these physicians and surgeons have been
trying to resolve this question by mining local and national
databases of past patients for answers. Further, they have been
working collaboratively, without the competition often seen at
other institutions. Together, they are not only trying to determine
which therapy to use in which cases, but more broadly what
characterizes “risk” in such patients. Does it mean diabetes,

coronary artery disease or respiratory problems? Which factors
really matter in determining a patient’s ability to survive surgery
and return to the best possible stamina and function?
“The colleagues we have aligned in thoracic surgery and
radiation oncology are unique,” says Bryan F. Meyers, MD, MPH,
chief of thoracic surgery and the Patrick and Joy Williamson
Professor of Surgery. “We scrutinize each other’s patient data
together, we go over each analysis together and we have no
shyness about challenging the other’s work. Our papers have
truly been joint efforts and represent our best effort to inform the
patients about the most likely outcomes from either modality.”
The result has been national prominence in this area for
Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and
Washington University School of Medicine. “Only a handful of
other institutions have looked at this problem in as much detail
as we have,” says Crabtree, assistant professor of surgery, who
was the first author on a 2010 study comparing groups of patients
treated with both therapies and tracking long-term outcomes.
Outlook 21

Removing the lobe of the
lung containing the cancer
has long been the recommended treatment for early-stage non-small cell lung cancer,
a biologically aggressive disease with a five-year survival of
60 to 75 percent. In recent years, cancer surgery has become
safer, with a surgical mortality rate of just 1 percent; recovery is also much easier because of the increasing dominance
of minimally invasive techniques. More than 75 percent of
lung cancer surgery at Barnes-Jewish Hospital is now done
using this approach.
“Large-incision patients will feel much worse than those
who have had three small incisions and cancer removal.
Small-incision patients go home sooner, feel better, are
less likely to need pain medications and are more likely to
be independent,” says Puri, assistant professor of surgery.
“Long-term, oncologically, this surgery provides equal
benefit to the big operation.”
These minimally invasive techniques mean thoracic surgeons are more likely to offer surgery to a patient with complicating conditions because they can do the operation more
safely than they could have a decade ago. Thus, the gray area
of patients who may or may not be candidates for surgery
has shrunk somewhat because of these surgical innovations.

Small-incision surgery
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RADIATION?

SURGERY?
JEFFREY BRADLEY, MD

Before they adopted SBRT as
a treatment option in 2004,
their results from the previous method — daily radiation for 35 treatments —were “just
lousy,” says Bradley, the S. Lee Kling Professor of Radiation
Oncology. Intrigued by reports of SBRT, he traveled to
Germany and Japan to learn the technique, and he and his
colleagues became national leaders in adopting it. They have
since treated some 500 patients, and the outcome “has been
excellent,” he adds. “Our primary tumor control rate is
better than 90 percent, and we’re thrilled with the results.”
SBRT works so well because it is a precisely targeted treatment in which radiation beams are arrayed around a tumor,
and the maximum dose is focused directly on the cancer,
minimizing the exposure of adjacent tissue. Specialized
equipment is necessary for the therapy: body-positioning
apparatus to keep the patient immobile for the 30-minute
session, and a linear accelerator with multi-slice CT imaging
that shows even slight tumor movement. Over a week’s time,
a patient has three to five treatments and then is done, with
little post-operative discomfort.
Bradley’s early advocacy for SBRT drew the attention
of thoracic surgeons, and his team began collaborating with
them on widely published multidisciplinary research.
Recently, Clifford Robinson, MD, assistant professor
of radiation oncology, became chief of the SBRT service.
The service has grown under Robinson’s leadership, and he
undertook surgery/SBRT analyses with Crabtree and Puri.
“Without Cliff’s work, we would not have been able to
accomplish these studies,” says Crabtree.

Precision radiation

These studies will better inform
patients and physicians regarding
probable therapeutic outcomes.

For those patients who fall
within the puzzling gray
zone, further research
is needed. After Crabtree’s 2010 paper in The Journal of
Thoracic and Cardiovascular Surgery, Puri — who has
received support from an NIH Career Development Award
and from the Foundation of Barnes-Jewish Hospital — was
principal author of an analytic modeling paper that looked
at cost-effectiveness for both options. These studies, based on
retrospective data, showed that surgery was somewhat more
expensive than SBRT but resulted in better overall survival.
In the gray-area patients, cancer-specific survival was similar
between SBRT and surgery.
For even more conclusive results, the best solution would
be to mount a prospective trial, randomizing new patients to
SBRT or surgery — but that has proved difficult. Three multicenter national trials have failed to accrue enough patients;
the last one, with Bradley as a principal investigator, closed
in May 2013. In large part, the reason is that patients have
strong opinions about the form of treatment they want.
“On one end of the spectrum, patients say: ‘I want this
out of me. Let me have surgery.’ On the other end, they say:
‘I am 75 years old, and you think I want to have a big surgery? If SBRT doesn’t work, I can have surgery afterward.’
It is hard to randomize patients because you’re taking the
choice away from them,” says Bradley.
Right now, he and his colleagues continue to plan new
studies. Thoracic surgeon Stephen Broderick, MD, is collecting data on the quality of life of lung cancer patients
treated either with surgery or with SBRT. In the short term,
Crabtree, Puri and Robinson hope to develop one computerbased algorithm for SBRT patients and another for surgery
patients, so that physicians will be able to describe their
chances of long-term survival with each method.

The gray zone
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Paradoxically, complex dance
moves could benefit patients
with movement disorders:
Gammon Earhart, PhD,
dances with participant Don Burr.
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It is fitting that Gammon Earhart
began her research career working with a device
that resembles a giant turntable. Music — tango
music in particular — has become an important
component of her work with Parkinson’s disease.
Earhart, PT, PhD, associate professor of physical therapy, neurology and neurobiology, used a
rotating treadmill for studies on healthy people
while she was a postdoctoral researcher at Oregon
Health & Science University. Her research demonstrated that when people walk on a rotating
surface for a period of time, then step off, they
are unable to walk in a straight line. The process
forces them to turn.
She took her research to Washington University
School of Medicine when she joined the faculty
of the Program in Physical Therapy in July 2004.
She began working with people with Parkinson’s
disease, a chronic and progressive movement
disorder that involves the malfunction and death
of neurons. As the disease progresses, people are
unable to control movement normally.
“Turning is something that people with
Parkinson’s disease are particularly troubled by,”
says Earhart, a member of the Movement Disorder
Center in neurology. “They try to make a turn but
get stuck and feel like their feet are glued to the
floor. That can lead to falls and the consequences
related to falls.”
One of her key goals is to help them make
turns. “It was that interest in turning behavior
— in healthy people and in Parkinson’s patients —
that eventually led me to the dance floor,” she says.
In 2005, Earhart attended a Society for
Neuroscience meeting and saw Canadian
24 Washington University School of Medicine

researchers present an abstract focused on frail,
elderly individuals randomly assigned either to
walk in a group for exercise or learn to dance the
tango. The researchers’ findings indicated that
those assigned to dance had improved their balance more than those assigned to walk.
When Madeleine Hackney, PhD ’09, a professional dancer turned graduate student, began
working in Earhart’s lab, it gave Earhart an idea.
“I thought, ‘Madeleine can certainly do the
tango.’ And after talking to her, Madeleine agreed
that we should try a pilot study incorporating the
dance for people with Parkinson’s,” she recalls.
It proved difficult to recruit patients at first.
Many thought they couldn’t dance — especially the tango — with a disease as limiting as
Parkinson’s. But eventually enough patients were
recruited, and the pilot study went well.
“The participants were pleasantly surprised at
how much they could still do, and they enjoyed it,”
Earhart says. “And our outcome measures showed
that, when compared with a group of people who
had taken a traditional exercise class, there were
more significant improvements regarding balance
and walking in the people in the tango group.”
Encouraged and excited by the results, Earhart
and Hackney moved forward with their research.
Subsequent studies have included 10 days of
classes over two weeks, which the researchers refer
to as “Tango Boot Camp,” to a study that offered
classes twice a week for a full year. The most typical design, however, offers classes twice a week for
three months.
Their findings have shown that tango-dancing
patients experience improvements that are as good
as or better than those who exercise using other
forms of dance, such as the waltz or fox-trot, or
alternative approaches, such as T’ai Chi.
Earhart theorizes that tango’s benefits come
from incorporating specific movements that people with Parkinson’s often have difficulty performing, such as walking backward.
The most important finding has come from the

year-long study. Participants were evaluated before
they started dancing and then again after three
months, six months and 12 months. This group
was compared with another group of people who
had Parkinson’s but were not exercising over the
same time period.
“We noted that at three months and then again
at six and then 12 months, the people who were
participating in tango dancing were improving
instead of deteriorating, which is unexpected
Autumn 2013

In a new study, supported by a recent $1.5 million
grant from the National Institute of Neurological
Disorders and Stroke, Earhart will compare tango
dancing to walking on a treadmill. She plans to
control for social factors as much as possible by
arranging the treadmills in clusters so participants
can talk to one another, as dance partners do.
In addition to evaluating each participant’s gait,
balance, cognitive function, severity of disease and
quality of life, Earhart will utilize neuroimaging
with functional MRI (fMRI) as part of the study.
Joel Perlmutter, MD, professor of neurology,
radiology, neurobiology, physical therapy and
occupational therapy, has a database that includes
more than 2,400 Parkinson’s patients, some of
whom may be potential candidates for Earhart’s
study, which calls for 120 participants.
“We hope to determine whether brain activity
or brain connections change as a result of participating in the exercise programs, and whether the
changes that result from tango dancing are the
same as or different from the changes that result
from using a treadmill,” Earhart says. “We want to
determine whether the changes we see in the brain
are related to changes in physical performance.”
Earhart says her research would be more difficult, if not impossible, if she were somewhere
other than the School of Medicine. “There’s no
way we could involve so many participants without the resources provided through the Movement
Disorder Center and the Greater St. Louis
American Parkinson Disease Association.”
outlook.wustl.edu

“We found that the people who were tango
dancing were improving instead of deteriorating,
which is unexpected for people with a
neurodegenerative disease like Parkinson’s.”
— Gammon Earhart, PT, PhD

ROBERT BOSTON PHOTOS

for people with a neurodegenerative disease like
Parkinson’s,” Earhart says. “That suggested we
were potentially modifying the trajectory of the
disease’s progression with participation in the
tango exercise program. That could have very
positive ramifications.”
Earhart noted other improvements in the
study participants’ lives, as well. Some picked up
activities they previously had given up, and some
engaged in new social activities. Increased activity
did not occur in the non-dancing group.
Susan Deusinger, PT, PhD, FAPTA, director of
the Program in Physical Therapy, says that Earhart
“has emerged as a leader in understanding the
neurological foundation of movement and how
degenerative diseases of the brain affect movement, health and function in daily life. While
her work is especially important for patients with
Parkinson’s disease, it also represents a line of
inquiry that blends basic and applied themes in
creative and innovative ways.”
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classnotes
1940 S

1960 S

Llewellyn Sale, MD 40
Sale, a resident of St. Louis MO, continued to work part-time until June 2011.
In retirement, he enjoys reading, mild
exercise and Wii bowling.

Melvin Dace, MD 62
Dace recently retired as Chief of Stadium
Medical Operations for the University of
Florida football team — the Florida
Gators — after having held the position
for 17 years. He also served as assistant
medical director of the 1996 Olympics in
Atlanta GA and for 25 years as a cardiologist in private practice.

Barber Mueller, MD 42
Mueller is retired and resides in Ontario,
Canada. He completed the final paragraphs of Excalibur, The Sword of Science
that Shaped the World, a book he had been
working on for the past eight to 10 years.
It brings an overview of ideas generated
during the Age of Science that have
forever changed our perception of the
universe and of man’s place on Earth.
John Wilson, MD 43
Wilson and his wife, Helen, recently
celebrated their 69th wedding anniversary. One of his fondest memories from
medical school is meeting Helen, a
Barnes Hospital dietitian, in the cafeteria.

1950 S
Rudenz Douthat, MD 54
Douthat is retired and living in
Fredericksburg TX. He has been honored
by the American College of Emergency
Physicians (ACEP). He looks forward to
reuniting and celebrating with fellow
1954 classmates at Reunion 2014.
Robert Winter, MD 58
Winter was honored by the Scoliosis
Research Society in 2012 with its Lifetime
Achievement Award and the founding
of the Robert B. Winter Global Outreach
Education Fund.

If you wish to make a tribute gift in honor
of any of the above alumni or faculty,
please contact: Pamela Buell, Washington
University Medical Alumni and Development,
Campus Box 1247, 7425 Forsyth Blvd., Suite 2100,
St. Louis MO 63105-2161, (314) 935-9691.
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John Crane, MD 64
Crane works two days a week at a mental
health clinic. He looks forward to celebrating his 50th wedding anniversary next
year with his wife, their three sons and
seven grandchildren. Crane and his wife
travel often in their small motor home
with yellow lab, Lily Pearl. He also enjoys
sailing with his sons at Carlyle Lake.
Doris Abrams, NU 67
Abrams retired after 43 years of practice in
various areas of pediatric nursing (neonatal ICU, med/surg, rehab, school nursing,
home care) and is now enjoying gardening, travel, reading, movies, theater and
maintaining “kid-kontact” at a local early
childhood center.

1970 S
Bruce Fisher, MD 70
After retiring from full-time work in 2011,
Fisher has been teaching at Jersey Shore
University Medical Center focusing on
clinical reasoning and basic bedside skills.
In 2012, he co-authored the 3rd edition
of Lippincott’s Illustrated Reviews:
Microbiology.
Marshall Bloom, MD 71
Bloom maintains an active career at the
National Institutes of Health as both chief
of the Tick-Borne Flavivirus Section and as
associate director for scientific management at Rocky Mountain Laboratories in
Montana. In 2011–12, he was chairman of
the organizing committee for the American
Society for Microbiology Biodefense and
Emerging Diseases Conference, and he was
elected a Fellow of the American Academy
of Microbiology in 2013.

Charles Ettelson, MD 78
Ettelson has retired from clinical practice
and started a second phase of his career
as a medical director at UnitedHealthcare,
St. Louis. He recently appeared as a contestant on “Jeopardy,” and his performance
is viewable on YouTube.

1980 S
Chris Pool, HA 83
Pool is with UnitedHealthcare Military
& Veterans Services as chief executive
officer for the Northwest region. He is
responsible for TRICARE field operations
for Washington, Oregon, Idaho, Montana,
Alaska and Northern California.
Margaret Steinhoff, MD 83
Steinhoff is director of surgical pathology and chair of the cancer committee
at Women and Infants Hospital of
Rhode Island.

1990 S
Joan Blomquist, MD 92
Blomquist is chief of the Division of
Urogynecology and Reconstructive Pelvic
Surgery at Greater Baltimore Medical
Center. Additionally, she travels annually
with the International Organization for
Women and Development to Niger and
Rwanda to perform and teach fistula
surgery.
Jane Chen, MD 93
Chen is an associate professor of medicine
in cardiology at Washington University
School of Medicine. She focuses her
practice on patients with diagnosed or
suspected heart rhythm abnormalities,
pacemakers or defibrillators and was recognized as a “Best Doctor” in 2011 by
St. Louis Magazine. She enjoys spending time with family (sons Marcus and
Harrison), reading and playing the piano.
Marc Seidman, MD 98
Seidman is a pediatrician living in
Fort Collins CO. He and his wife have
two daughters, Gabi and Anna.
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2000 S
Jared Hershenson, MD 04
After completing a pediatric cardiology
fellowship at Nationwide Children’s
Hospital in Columbus OH, Hershenson is
now working in the greater Washington
DC area with Child Cardiology Associates.
Andrew Zimolzak, MD 07
Zimolzak completed an internal medicine
residency and chief resident year at Saint
Louis University. He is now enrolled in a
master’s program in medical informatics at
Harvard Medical School. He and Elizabeth
Moulton, GM 11, MD 11, are engaged.
Michelle Moniz, MD 08
Moniz has been selected as a 2013
Robert Wood Johnson Foundation
Clinical Scholar. She will conduct innovative research and work with communities,
organizations, practitioners and policymakers to take a leadership role in
improving health and health care in the
United States. Her fellowship begins at the
University of Michigan in fall 2013.

I M
Jane Arax Erganian, BA 37, MD 41
Erganian died on March 3, 2013. She was
96. She pursued a specialty in pediatrics.
While a resident at New York Hospital,
she met her husband, Armig G. Kandoian.
With him she raised three daughters and
eventually returned to her profession,
enjoying many years as Senior Public
Health Physician for the New Jersey State
Department of Health.
Vergil Slee, MD 41, MPH
Slee died at age 94 on July 31, 2012.
After completing a medical internship at
Barnes Hospital, he became a flight surgeon for the U.S. Air Force, then earned an
MPH from the University of Michigan. He
founded the Professional Activity Study
(PAS), the prototype of computerized
hospital discharge systems used today.
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John Farrar, MD 45
Farrar died on June 26, 2012, at age 92.
After serving in the U.S. Army Medical
Corps, he trained in gastroenterology.
He taught at Boston University School of
Medicine and Cornell University College
of Medicine before becoming the chair
of the Division of Gastroenterology at
the Medical College of Virginia (now VCU
Medical Center). He served in several positions for the U.S. Department of Veterans
Affairs. After retiring, he remained active
in medicine and in his community.
Henry Hosford, MD 51
Hosford died on June 13, 2012. A World
War II U.S. Army veteran and New Mexico
native, he moved to St. Louis to attend
Washington University School of Medicine
and receive medical training. He returned
to New Mexico and practiced medicine
there for more than 50 years.
Prudence D’Angelo, NU 52
D’Angelo died on Sept. 18, 2012, at
age 83. She was a pediatric nurse.
John Commerford, MD 53
Commerford died on Feb. 4, 2012. He
served as a medical officer in the Public
Health Service. He moved to St. Charles
MO, where he was a partner in a private
medical practice, practiced with Boonslick
Medical Group, and had hospital privileges
at St. Joseph’s Hospital where he served as
chief of family practice and chief of staff.
Andrew McCanse, MD 54
McCanse died on July 21, 2012. He served
in the U.S. Army in Korea before returning to Jewish Hospital for a surgical residency. He practiced general surgery for
22 years and became the first chair of the
Department of Surgery at the University of
Missouri-Kansas City School of Medicine.
Later he switched his specialty to occupational medicine, which he practiced until
his retirement.
Richard Braun, MD 55
Braun died on Dec. 2, 2012. After medical school, Braun and his wife, Gertrude
Braun, NU 54, served together at hospitals in Ghana caring for patients and training nurses and medical students. Later
he worked on the board of the Tennessee
Health Care Campaign.

Patricia Simpson, NU 55
Simpson died on Jan. 2, 2012, in Memphis
TN. She spent 42 years as a registered
nurse and was a nursing home administrator for 22 of them.
John Vander Woude, MD 78, HS 85
Vander Woude died on July 10, 2012. He
was 58. After graduation, he entered the
surgical residency program at Washington
University School of Medicine. He moved
to Texas for a cardiovascular surgery fellowship and completed a fellowship in
pediatric cardiac surgery at the University
of California, San Francisco. He was director of cardiothoracic surgery at Sanford
USD Medical Center in Sioux Falls SD. He
participated in surgical and medical missions in Kenya, China and Ecuador as well
as volunteer work in his home community.
Ira C. Gall, MD, HS
Gall died on March 29, 2013. After
completing his medical degree at the
University of Cincinnati, Gall served as a
physician in the U.S. Air Force before
moving to St. Louis to complete a residency in obstetrics and gynecology. He
went on to practice medicine at Barnes
Hospital and later co-created Obstetrics
and Gynecology, Inc., and Medicine
Shoppe International. He was a philanthropist and strong community supporter.

F
George Sato, MD 47, LA 96
Sato died on Feb. 5, 2013. In addition to
his private pediatrics practice, Sato was a
clinical professor at Washington University
School of Medicine. He received the
Washington University Medical Center
Alumni Association Alumni Achievement
Award in 1982.
Benje Boonshaft, LA 57, MD 61
Boonshaft died on June 24, 2012, at
age 76. An assistant professor emeritus
of clinical medicine, he served in the
U.S. Air Force Hospital during the
Vietnam War. He helped build and cofound Willowbrook Medical Center in
Creve Coeur MO and was an internist
for the St. Louis Blues.
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The Campaign for Washington University

Cancer and
personalized
medicine

BY STEPHANIE STEMMLER

We are redefining how cancer is diagnosed and treated.

PHOTOS BY ROBERT BOSTON

Alvin J. Siteman, left, had
an extraordinary vision:
Create an “institution
of world-class cancer
research, combined with
compassionate cancer care,
to provide longer life and
lasting hope for generations
to come.” Such partnerships
are led by Timothy J.
Eberlein, MD, director of the
Siteman Cancer Center, the
Spencer T. and Ann W. Olin
Distinguished Professor and
chair of the Department
of Surgery at the School
of Medicine.

At the forefront of personalized medicine, Washington University is
conducting groundbreaking research to identify genetic and molecular
changes that trigger cancer. We are translating that research into
innovative diagnostic tools for individualized treatment. Our
oncologists and radiologists are inventing better technologies to
identify cancers and pinpoint their treatments. The result? Patients
receive personalized care that is more effective and easier to tolerate.
More than 350 Washington University physicians and
researchers are engaged in cancer treatment and research. And
the Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and
Washington University School of Medicine serves more than 50,000
cancer patients annually. From prevention to care, education, research
and outreach, Siteman Cancer Center is recognized as one of the great
Comprehensive Cancer Centers in the United States by the National
Cancer Institute. Our physicians help set national and global standards
for cancer treatment as one of only 23 centers in the National
Comprehensive Cancer Network.
Physicians at the School of Medicine and Siteman use a
collaborative, multidisciplinary team approach to tackling cancer.
Through investments in prevention, education, care and research, they
say, the day will come when most cancers are preventable or treatable.

Partner with us to reach that attainable goal.
outlook.wustl.edu
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Linda and Harvey Saligman, center, support the multiple myeloma research of John F. DiPersio, MD, PhD, left, and Ravi Vij, MD.

Multifaceted efforts
Wanting to make a difference in the fight

against cancer, Harvey Saligman and his wife,
Linda, saw an ideal opportunity. Diagnosed with
multiple myeloma seven years ago, Saligman
discovered that even though his disease was
one of the most common types of blood cancer
(lymphoma and leukemia among them), most
research dollars went to other types of cancer.
“I’m convinced that this particular cancer can be cured,” Saligman
says. “We wanted to accelerate
“We’ve already made
that time frame by supporting
great strides in improving
research efforts.”
The Harvey and Linda Saligman
the life expectancy of
Multiple Myeloma Research Fund,
patients with multiple
established in 2009, is paying divimyeloma by helping to
dends in terms of cancer research
find new therapies as a
accomplishments. In the past year,
result of this gift.” two new drugs have received federal
approvals to treat multiple myeloma,
— JOHN F. DIPERSIO, MD, PHD
both the result of clinical trials in
which Washington University was
a leading research site.
The university also has established a large
myeloma tissue bank for ongoing research and
is a member of the Multiple Myeloma Research
Consortium — 13 U.S. academic centers focused
on speeding the development of new therapies.
30 Washington University School of Medicine

“Thanks to support from the Saligmans, we’ve
been able to get a critical mass of basic science
researchers to focus on this disease and broaden
our multifaceted effort to study the biology of
multiple myeloma,” says Ravi Vij, MD, associate
professor of medicine in the Division of Oncology.
“It also enables us to conduct clinical trials, which
are leading to new medications, such as the two
that were recently approved.”
“We’ve already made great strides in improving the life expectancy of patients with multiple
myeloma by helping to find new therapies as a
result of this gift,” says Division of Oncology
Chief John F. DiPersio, MD, PhD, the Virginia E.
and Sam J. Golman Professor of Medicine
in Oncology.
“It is so exciting to see the young scientists
who actually are doing this work,” says Linda
Saligman. “Because of their efforts, there is hope.
Now that some of the research is also focused
on the potential inherited aspect of this disease,
there is hope for generations to come.”
Adds Harvey Saligman, “I’ve seen unbelievable
advances in myeloma research here. The best part
about going public about our own experience
with this disease is that hopefully it will attract
other people to give so that the momentum we
have going can really make a difference.”
Autumn 2013
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Timothy J. Ley, MD, left, Elaine R. Mardis, PhD, and Richard K. Wilson, PhD, use genome sequencing to understand the roots of cancer.

Seeking cancer’s roots
As genomic discovery research finds more
genes that are commonly altered, leading to various types of cancer, treatment will focus not only
on the body part being treated — breast, colon or
prostate, for example — but also on the genetic
blueprint of the disease.
“Precision cancer medicine will mean that
therapeutic decisions are based on the underlying
mutations in each patient’s tumor,”
says Elaine R. Mardis, PhD, codirector of The Genome Institute
at Washington University.
More than 10 years ago, Institute
scientists played a leading role in
an international effort, the Human
“You can’t do precision
Genome Project, that decoded the
medicine without the
complete sequence of human DNA.
Today,
the Institute is one of only
basic genome work
three
U.S.
large-scale genomic cenhappening first.”
ters funded by the National Institutes
— RICHARD K. WILSON, PHD
of Health (NIH).
In the fight against cancer,
research at the Institute has breathtaking consequences. In 2008, a team of researchers
led by Timothy J. Ley, MD, the Lewis T. and
Rosalind B. Apple Professor of Oncology, was
the first to sequence the entire genome of a cancer
patient, a woman diagnosed with acute myeloid
outlook.wustl.edu

leukemia (AML), thanks to a generous gift
from Alvin J. Siteman. By comparing her cancer
genome to similar data obtained by sequencing
the patient’s healthy cells, the team identified 10
mutated genes, setting the stage for using nextgeneration sequencing and analysis to decode
hundreds of cancer cases.
Now Institute researchers have completely
sequenced the DNA from paired tumor cells and
healthy cells of more than 1,000 patients, effectively
transforming the field of cancer genomics. The
resulting data has had profound consequences
for understanding the genetic basis of cancer, has
identified key genes related to predicting outcome
in several cancer types and has helped researchers
consider how to make cancer therapy choices
more precise, based on the mutations underlying
individual tumors.
Researchers say more funding could speed up
whole genome sequencing for oncology. Six years
ago, sequencing the whole genome of the AML
patient took eight months. Today, it takes 28 hours.
“I envision going from completing whole genome
sequencing for 12 patients a year to hundreds of
patients a day,” says Institute director Richard K.
Wilson, PhD. “We need to make this process more
efficient; you can’t do precision medicine without
the basic genome work happening first.”
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Herbert “Skip” W. Virgin, MD, PhD, left, and Jeffrey D. Milbrandt, MD, PhD, combine genetics and genomics to provide clinical care.

Combined strengths
Sitting at a kitchen table one night

years ago, Jeffrey D. Milbrandt, MD, PhD, and
Herbert “Skip” W. Virgin IV, MD, PhD, hashed
out an idea that would help revolutionize medicine. Milbrandt, the head of the department of
genetics, and Virgin, the head of pathology and
immunology, would combine their departments’
strengths in genetics and genomics and clinical
laboratory testing to change the
way diseases are diagnosed and
patients are treated.
Melding their expertise, faculty,
staff
and resources, the two estab“The issue now is how fast
lished Genomics and Pathology
can we do [genome testing]
Services, or GPS, a clinical genomand how many patients and
ics testing service that provides a
diseases can we impact?
distinct road map for physicians
This is a game-changer. ” on how best to treat a person’s
specific disease based upon his or
— HERBERT “SKIP” W. VIRGIN,
her own genetic variation. They
MD, PHD
call it “precision or personalized
medicine.”
“This is not research, this is
actual clinical care,” stresses Milbrandt, the
James S. McDonnell Professor of Genetics.
“We wanted to take genomics research and
make it matter to patients today.”
32 Washington University School of Medicine

Testing can identify gene mutations that impact
the course of treatment. Once identified, available
targeted drug therapies can be used. They started
with cancer and saw results almost immediately.
They found that one patient whose metastatic cancer was unresponsive to treatment had uncommon
genetic mutations. When they offered a different
class of drugs targeting those mutations, the
tumors decreased in size within one month.
“We’ve proven we can impact care with this type
of testing,” says Virgin, the Edward Mallinckrodt
Professor of Pathology and Immunology. “We’ve
done more than 1,000 cases of cancer already, and
we’re finding mutations in those cancers that we
didn’t expect to find.”
More resources could expand the testing platform to include other genes. Funding also could
help the team expand translational research trials
to identify more targeted drug therapies and allow
them to evaluate long-term patient outcomes.
“We know what to do, and we’re moving
beyond cancer to include sudden cardiac death,
kidney disease and congenital birth defects, to
name a few,” says Milbrandt.
Says Virgin, “The issue now is how fast can
we do this and how many patients and diseases
can we impact? This is a game-changer.”
Autumn 2013
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Matthew J. Ellis, MB, BChir, PhD, tailored breast cancer treatments for patient Jeanne Imbs Weitzel.

Genetic fingerprints
The time is coming when all patients

diagnosed with cancer will undergo a biopsy
to identify the genetic fingerprint of their specific
tumor, then receive tailored therapy to kill it.
Groundbreaking research at Washington
University School of Medicine is focused on
attacking breast cancer at its genetic roots.
Last year, a team of researchers, including
Matthew Ellis, MB, BChir, PhD,
chief of breast oncology at
Washington University and the
Anheuser-Busch Professor of
Medical Oncology, discovered that
“Discoveries here are
breast cancer could be divided into
paving the way for
four distinct types, all genetically
clinical trials and have the
different and all of which respond
differently
to various treatments.
potential to affect millions
“Not
all
breast cancers are alike.
of breast cancer patients.”
We know that certain medications
— MATTHEW J. ELLIS,
are highly effective against broad
MB, BCHIR, PHD
types of breast cancer, but some
women don’t respond well to
those treatments,” Ellis says.
“Instead of relying on a general ‘recipe’ for
combating breast cancer, we need to individualize treatment. We can do that by looking at the
genetic components of each patient’s cancer.”
outlook.wustl.edu

Already Ellis and other researchers have found
that a form of breast cancer is genetically more
similar to ovarian cancer than to breast cancer,
which has striking implications for treatment
strategies. Clinical trials here led to the development of a diagnostic test now under review by
the U.S. Food & Drug Administration. The test,
currently for patients with hormone receptorpositive (HR+) early-stage breast cancer, classifies
the cancer and the risk for recurrence based on
the biologic components of each patient’s tumor.
Ellis hopes the test will receive federal approval
later this year.
“Just in the last three years, the research has
undergone dramatic advances,” says Jeanne Imbs
Weitzel, who benefited from clinical trials. Gene
analysis revealed that her cancer would likely not
respond to chemotherapy following a mastectomy.
Instead she was prescribed an estrogen-suppressing
drug. “I wish every woman with breast cancer could
experience this kind of personalized approach.
Dr. Ellis gave me complete confidence that the
treatment he prescribed was the most appropriate
to combat my type of breast cancer.” Weitzel goes
on to say, “Dr. Ellis is both brilliant and compassionate; at every appointment I felt like his only
patient. His caring approach has had a tremendous
impact on my ability to heal.”
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Jeff M. Michalski, MD, left, uses radiation therapy to treat patients like Michael Pulitzer.

Innovative imaging
It’s all about targeting in the battle against

cancer. The arsenal to deliver highly targeted radiation therapy for patients with prostate or bladder
cancer will soon include new technology evaluated
by Washington University radiation oncologists.
“There’s no technology today that allows us
to see inside a patient and treat a tumor at the
same time. Instead, we use images obtained before
radiation treatments to determine a
tumor’s size and location,” says Jeff
M. Michalski, MD, the Carlos Perez
Professor of Radiation Oncology
and vice chair of radiation oncology. “The problem is that tumors
“Just as neurosurgeons
can shift due to breathing or other
need to see a tumor as
movement. Just as neurosurgeons
they remove it, radiation
need to see a tumor as they remove
it,
radiation oncologists need to see
oncologists need to see the
the tumor while they radiate.”
tumor while they radiate.”
Radiation oncologists here are
— JEFF M. MICHALSKI, MD
evaluating a first-of-its-kind, combined MRI imaging and intensitymodulated radiation therapy
(IMRT) system that provides continuous images
of a tumor during treatments. Clinical trials,
exclusive to the Alvin J. Siteman Cancer Center,
are seeking to measure the value of the technology
in cancer therapy.
34 Washington University School of Medicine

“We have a long-standing reputation for innovation in imaging and radiation therapy,” says
Michalski, an internationally recognized radiation
oncologist who has multiple studies under way
to enhance treatment outcomes for prostate cancer
patients. His latest clinical trials focus on combining radiation and hormone-suppression therapy
(androgen deprivation) to try to pinpoint the
optimal duration and amount of each while
minimizing side effects.
Michael Pulitzer recognizes the strength of
Michalski’s research and its impact on patients
like him. He characterizes Washington University
as having one of the best radiation therapy centers
in the world. “The care I received was seamless,”
says Pulitzer, who made an unrestricted donation
to support Michalski’s research. “As a result,
I have what could be called ‘grateful patient’
syndrome. Dr. Michalski cured me, and I want
to help him cure others.”
Michalski wants to collaborate with other
researchers to find specific genes that impact treatment. “Each patient’s tumor biology may uniquely
respond to radiation therapy, and we could tailor
the treatment to maximize its benefits. We need
to push ourselves beyond what we already know
because that results in better, more effective
cancer treatments and outcomes,” he says.
Autumn 2013

ROBERT BOSTON

David G. Mutch, MD, chief of gynecologic oncology, with Ina Sachar, who has benefited from new therapies and research.

Finding new therapies
“I don’t have time for cancer,” says Ina

Sachar, who has lived with cancer for 20 years.
Instead, the 66-year-old St. Louis resident has four
grandchildren to spoil and places she wants to
travel. She embodies the strength of the human
spirit and the advances made to eradicate cancer.
Sachar has battled cancer since 1993 — first
breast cancer, then ovarian, endometrial and
colon cancer. While the ovarian
cancer has recurred, she has fought
back each time with new drug
therapies that have become available
over the past two decades.
“I’ve been the beneficiary of
“We have very good
targeted therapies and the research
therapies because of
that’s been done at Washington
all the clinical trials and
University and the Siteman Cancer
Center,”
Sachar says.
genomic research done at
The
university
currently has
Washington University.”
35 different gynecologic oncol— DAVID G. MUTCH, MD
ogy clinical trials open and active.
Washington University researchers
are among the largest contributors to a national consortium, the Gynecologic
Oncology Group.
“We have very good therapies because of all
the clinical trials and genomic research done at
Washington University,” says David G. Mutch,
outlook.wustl.edu

MD, chief of the division of gynecologic oncology,
where six oncologists all work together. “We can
practice state-of-the-art care because we are at a
great university where all areas are excellent.”
Because of their record of excellence in patient
care and research, Washington University and
Siteman Cancer Center received the National
Cancer Institute’s first Specialized Program of
Research Excellence (SPORE) grant to accelerate
research into causes and treatments for endometrial cancer. The multi-year grant, awarded
in 2010, is showing results.
“We’ve identified more accurate, cost-effective
ways to screen patients for an inheritable form of
endometrial cancer that could be available to the
public in the next year or so,” says Mutch, the
Ira C. and Judith Gall Professor of Obstetrics
and Gynecology. “We’re also learning more about
the molecular makeup of this cancer and the
gene mutations that impact the success or failure
of treatment options.”
Research has correlated a genetic link between
ovarian and breast cancer and between inherited
versions of endometrial cancer and colon cancer.
More effective, targeted treatments for gynecologic
cancers might benefit all cancer patients.
Says Sachar, “The reason to fund research like
this is that they will find secrets to many cancers.”
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We are redefining how cancer is diagnosed and treated.
Please consider funding this or other opportunities to
advance human health.
Cancer and Personalized Medicine
n

Endowed professorships for specific departments
or diseases

n

Endowed research funds for specific departments
or diseases

n

Endowed gifts to be recognized by naming an institute,
center or research laboratory

n

Annual or endowed fellowship support
for physician-scientists

n

Expendable support for three- to five-year pilot projects

n

Annual unrestricted support

The Brain

For information
about these and other
opportunities, please
contact:
Pamela Buell
Associate Vice Chancellor
for Medical Alumni and
Development

Phone:
(314) 935-9691
Email:
meddev@wustl.edu
Website:
medicalalumni.wustl.edu /
campaign

Diabetes, Heart Disease, and Obesity
Infectious Diseases and Global Health

Together,

we can change lives.
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Professors, Graduate Fellows, and Students
The Annual Fund
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At the top

COURTESY OF GOSIA BORCHARDT

On May 18, 2013, Gosia Borchardt, a
Washington University nurse anesthetist at
Barnes-Jewish Hospital, fulfilled a long-time
goal: She reached the top of the world, the
summit of Mt. Everest. Her quest to climb
the highest peaks on all seven continents
— the Seven Summits — has taken her
to the top of Mt. Kilimanjaro in Africa
(2007), Mt. Elbrus in Europe (2009) and
Mt. Aconcagua in South America (2010).
An injury on the Aconcagua climb resulted
in thoracic outlet syndrome (TOS), surgery
by Washington University vascular surgeon
Robert Thompson, MD, and a long recovery.
The Everest climb was the culmination of
five years of planning and training. On her
way back to base camp, she posted on
Facebook: “I still can’t believe I made it all
the way up to the summit.”
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Lung cancer therapy
When is it best to use targeted
radiation, and when should
physicians advocate minimally
invasive surgery? Research will
provide a better basis for making
the optimal decision in each case.
This scan of a patient’s body shows
the paths of the radiation beams
planned for his therapy. The
precise convergence of multiple
beams amplifies their effects on
the tumor. For more on this story,
please turn to page 20.
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